Citations

Clear

4610 citation(s) found for "Lu, Brian".

Simulating the Effects of Embolic Coils on Cerebral Aneurysm Fluid Dynamics Using Finite Element Modeling
Babiker, M. Haithem, Gonzalez, L. Fernando , Chong, Brian W. , Frakes, David

Mayo Clinic

Volume 1B: Extremity; Fluid Mechanics; Gait; Growth, Remodeling, and Repair; Heart Valves; Injury Biomechanics; Mechanotransduct | January 29, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/sbc2013-14417 Get It

Endovascular coiling is the most common treatment for cerebral aneurysms. The treatment consists of deploying coils of different shapes and sizes into the aneurysm with the intent of reducing blood flow therein. While the treatment has been shown to be more effective than conventional surgical methods, it is successful in only 50–80% of cases, depending on the type of aneurysm [1]. Treatment success has been correlated with favorable post-treatment hemodynamics [2]. Understanding of the effects of coils on post-treatment hemodynamics is limited, however, due to limited in-vivo and in-vitro flow measurement techniques. Previous computational studies have also suffered from drastic assumptions about coil geometry.
Genetically adjusted prostate‐specific antigen values may prevent delayed biopsies in A frican‐ A merican men
Donin, Nicholas M. , Loeb, Stacy , Cooper, Phillip R. , Roehl, Kimberly A., Baumann, N, Catàlona, William J. , Baumann, Nikola A, Helfand, Brian T. , Loeb, Stacy

Mayo Clinic

BJU International | January 27, 2014 | Volume: 114 | Issue: 6b | Pages: No page available

10.1111/bju.12647 | PMID 24712975 Get It

Objective To evaluate whether genetic correction using the genetic variants prostate‐specific antigen ( PSA )‐single nucleotide polymorphisms ( SNPs ) could reduce potentially unnecessary and/or delayed biopsies in A frican‐ A merican men. Subjects and Methods We compared the genotypes of four PSA ‐ SNPs between 964 C aucasian and 363 A frican‐ A merican men without known prostate cancer ( PCa ). We adjusted the PSA values based on an individual's PSA‐SNP carrier status, and calculated the percentage of men that would meet commonly used PSA thresholds for biopsy (≥2.5 or ≥4.0 ng/mL) before and after genetic correction. Potentially unnecessary and delayed biopsies were defined as those men who were below and above the biopsy threshold after genetic correction, respectively. Results Overall, 349 (96.1%) and 354 (97.5%) A frican‐ A merican men had measured PSA levels <2.5 and <4.0 ng/mL. Genetic correction in A frican‐ A merican men did not avoid any potentially unnecessary biopsies, but resulted in a significant ( P < 0.001) reduction in potentially delayed biopsies by 2.5% and 3.9%, based on the biopsy threshold level. Conclusions There are significant differences in the influence of the PSA ‐ SNPs between A frican‐ A merican and C aucasian men without known PCa , as genetic correction resulted in an increased proportion of A frican‐ A merican men crossing the threshold for biopsy. These results raise the question of whether genetic differences in PSA might contribute to delayed PCa diagnosis in A frican‐ A merican men.
Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK
Liu, Xiaona , Chhipa, Rishi Raj , Pooya, Shabnam, Wortman, Matthew D. , Yachyshin, Sara, Chow, Lionel M.L. , Zhou, Xuan , McPherson, Christopher, Warnick, Ronald E. , Kendler, Ady , Poels, Jeroen, Norga, Koen , Viollet, Benoı̂t , Grabowski, Gregory A. , Dasgupta, Biplab , Kumar, Ashish , Sun, Ying Hao , Quinn, Brian , Giri, Shailendra , Viollet, Benoit

Mayo Clinic

Proceedings of the National Academy of Sciences | January 13, 2014 | Volume: 111 | Issue: 4 | Pages: No page available

10.1073/pnas.1311121111 | PMID 24474794 Get It

Significance Cancer cells reprogram their metabolism for optimal growth and survival. AMPK-activated protein kinase (AMPK) is a key energy sensor that controls many metabolic pathways including metabolic reprogramming. However, its role in cancer is poorly understood. Some studies claim that it has a tumor suppressor role while others show its protumor role. Two AMPK-activating compounds (including metformin, now in many clinical trials) are widely used to suppress cancer cell proliferation. We found that AMPK is abundantly expressed in high-grade gliomas and, in contrast to popular belief, these two AMPK activators suppressed glioma cell proliferation through unique AMPK-independent mechanisms.
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, Antonio , Miguel, Jesús F. San , Larocca, Alessandra , Niesvizky, Rubén, Morgan, Gareth J. , Hájek, Roman , Dimopoulos, Meletios Α. , Richardson, Paul G. , Cavo, Michèle , Spencer, Andrew , Stewart, A. Keith, Shimizu, Kazuyuki , Sonneveld, Pieter , Durie, Brian G.M. , Moreau, Philippe , Orlowski, Robert Z. , Rajkumar, S. Vincent , Landgren, Ola , Einsele, Hermann , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Lonial, Sagar , Orlowski, Robert Z. , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | January 13, 2014 | Volume: 32 | Issue: 6 | Pages: 587-600

10.1200/jco.2013.48.7934 | PMID 24419113 Get It

Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.
The two faces of neuromyelitis optica
Weinshenker, Brian G. , Wingerchuk, Dean M. , Weinshenker, Brian G

Mayo Clinic

Neurology | January 11, 2014 | Volume: 82 | Issue: 6 | Pages: 466-467

10.1212/wnl.0000000000000114 | PMID 24415570 Get It

Thyroid Hormone-Responsive Pituitary Hyperplasia Independent of Somatostatin Receptor 2
Brinkmeier, Michelle L. , Stahl, Justin H., Gordon, David F. , Ross, Brian D. , Sarapura, Virginia D. , Dowding, Janet M., Lloyd, Ricardo V., Ridgway, E. Chester, Camper, Sally A. , Kendall, Susan K.

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 15 | Issue: 12 | Pages: 2129-2136

10.1210/mend.15.12.0744 | PMID 11731614 Get It

AbstractMice homozygous for the targeted disruption of the glycoprotein hormone α-subunit (αGsu) display hypertrophy and hyperplasia of the anterior pituitary thyrotropes. Thyrotrope hyperplasia results in tumors in aged αGsu−/− mice. These adenomatous pituitaries can grow independently as intrascapular transplants in hypothyroid mice, suggesting that they have progressed beyond simple hyperplasia. We used magnetic resonance imaging to follow the growth and regression of thyrotrope adenomatous hyperplasia in response to thyroid hormone treatment and discovered that the tumors retain thyroid hormone responsiveness. Somatostatin (SMST) and its diverse receptors have been implicated in cell proliferation and tumorigenesis. To test the involvement of SMST receptor 2 (SMSTR2) in pituitary tumor progression and thyroid hormone responsiveness in αGsu−/− mutants, we generated Smstr2−/−, αGsu−/− mice. Smstr2−/−, αGsu−/− mice develop hyperplasia of thyrotropes, similar to αGsu−/− mutants, demonstrating that SMSTR2 is dispensable for the development of pituitary adenomatous hyperplasia. Thyrotrope hyperplasia in Smstr2−/−, αGsu−/− mice regresses in response to T4 treatment, suggesting that SMSTR2 is not required in the T4 feedback loop regulating TSH secretion.
Lack of Impact of Radioiodine Therapy in Tg-Positive, Diagnostic Whole-Body Scan-Negative Patients with Follicular Cell-Derived Thyroid Cancer
Fatourechi, Vahab , Javedan, Houman , Wiseman, Gregory A., Mullan, Brian P., Gorman, Colum A., Hay, Ian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 8, 2014 | Volume: 87 | Issue: 4 | Pages: 1521-1526

10.1210/jcem.87.4.8373 | PMID 11932275 Get It

Single-Agent Rituximab for Primary CNS Lymphoma During Pregnancy As a Bridge to Definitive Management
Burnette, Brian L., Jentoft, Mark A., Porrata, Luis F. , Boyce, Thomas G. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 7, 2014 | Volume: 32 | Issue: 7 | Pages: e14-e17

10.1200/jco.2012.47.6994 | PMID 24395859 Get It

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein‐10 predicts inferior prognosis in untreated diffuse large B‐cell lymphoma
Maurer, Matthew J. , Stenson, Mary, Allmer, Cristine, Macon, William R. , Link, Brian K. , Katzmann, Jerry A., Witzig, Thomas E. , Gupta, Mamta , Maurer, Matthew , Link, Brian K

Mayo Clinic

American Journal of Hematology | January 2, 2014 | Volume: 89 | Issue: 4 | Pages: 417-422

10.1002/ajh.23658 | PMID 24382707 Get It

The detection of serum free light (FLC) is useful in the diagnosis of several hematological diseases. The role and biological relevance of monoclonal or polyclonal FLC elevations in predicting long‐term outcome in diffuse large B‐cell lymphoma (DLBCL) is unknown. We determined the relationship of the type of FLC elevations to outcome, tumor genotype, and pattern of serum cytokine elevations in 276 patients with untreated DLBCL. Elevated FLC was an adverse prognostic factor through 6 years of follow‐up (monoclonal, Event free survival (EFS) HR = 3.56, 95% CI: 1.88–6.76, P <0.0001; polyclonal, EFS HR = 2.56, 95% CI: 1.50–4.38, P = 0.0006). About 73% of DLBCL tumors with monoclonal FLC elevations were activated B‐cell type (ABC) versus 33% from patients with normal FLC. Only ABC‐DLBCL lines secreted kappa FLC in vitro and this secretion could be inhibited by the NF‐κB inhibitor bortezomib. Patients with monoclonal FLC had significantly (all P <0.001) increased serum levels of IL‐12, sIL‐2Rα, IL‐1R, and IP‐10. Patients with polyclonal elevations of FLC had higher levels of IL‐6 (P = 0.033), IL‐8 (P =0.025), sIL2Rα (P = 0.011), and IL‐1R1 (P = 0.041). The combination of elevated FLC and a CXC superfamily chemokine IP‐10 predicted a particularly inferior outcome characterized by late relapse. These increased abnormal FLC and cytokines are potentially useful biomarkers for prognosis and selecting agents for untreated DLBCL. Am. J. Hematol. 89:417–422, 2014. © 2014 Wiley Periodicals, Inc.
Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack
Katz, Brian, Flemming, Kelly D. , Katz, Brian S, Flemming, Kelly D

Mayo Clinic

Neurosurgical Focus | January 1, 2014 | Volume: 36 | Issue: 1 | Pages: E10

10.3171/2013.10.focus13402 | PMID 24380476 Get It

In addition to appropriate antithrombotic therapy, the identification and treatment of modifiable ischemic stroke risk factors can reduce the likelihood of recurrent stroke. Neurosurgeons should be knowledgeable of the specific risk factors and general recommendations for ischemic stroke, as they may play a significant role in the management options for patients with intracranial and extracranial atherosclerotic disease. The authors of this article review the indications for and selection of antithrombotics in patients with cerebral ischemia. In addition, the identification and secondary prevention of select risk factors are discussed.